Globe Life (NYSE:GL) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Globe Life (NYSE:GL) announced its quarterly earnings results on Wednesday. The company reported $3.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.46 by ($0.03), FiscalAI reports. Globe Life had a return on equity of 21.30% and a net margin of 19.37%.The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the previous year, the company posted $3.07 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Globe Life updated its FY 2026 guidance to 15.400-15.90 EPS.

Globe Life Stock Up 0.3%

GL opened at $151.36 on Thursday. The business’s fifty day simple moving average is $143.31 and its 200 day simple moving average is $139.29. Globe Life has a 52 week low of $111.13 and a 52 week high of $152.80. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.39. The stock has a market cap of $11.87 billion, a PE ratio of 10.75 and a beta of 0.47.

Globe Life Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Friday, April 3rd will be paid a $0.33 dividend. This is a boost from Globe Life’s previous quarterly dividend of $0.27. This represents a $1.32 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, April 2nd. Globe Life’s payout ratio is currently 9.38%.

Insider Activity

In other Globe Life news, CEO Frank M. Svoboda sold 12,500 shares of Globe Life stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $144.78, for a total transaction of $1,809,750.00. Following the transaction, the chief executive officer directly owned 35,868 shares of the company’s stock, valued at approximately $5,192,969.04. This trade represents a 25.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Robert Edward Hensley sold 712 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $142.59, for a total transaction of $101,524.08. Following the completion of the sale, the executive vice president owned 8,580 shares of the company’s stock, valued at approximately $1,223,422.20. The trade was a 7.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 82,807 shares of company stock valued at $12,041,286. 2.11% of the stock is owned by insiders.

Hedge Funds Weigh In On Globe Life

Large investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in Globe Life by 2.7% during the fourth quarter. Invesco Ltd. now owns 3,948,676 shares of the company’s stock valued at $552,262,000 after buying an additional 102,445 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Globe Life by 2.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,135,861 shares of the company’s stock valued at $298,732,000 after acquiring an additional 59,629 shares during the last quarter. Morgan Stanley lifted its stake in shares of Globe Life by 7.2% in the 4th quarter. Morgan Stanley now owns 1,860,257 shares of the company’s stock valued at $260,176,000 after acquiring an additional 125,567 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Globe Life by 98.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,402,690 shares of the company’s stock valued at $174,340,000 after acquiring an additional 696,548 shares during the period. Finally, Nuveen LLC boosted its holdings in Globe Life by 20.4% during the 4th quarter. Nuveen LLC now owns 1,374,302 shares of the company’s stock valued at $192,210,000 after acquiring an additional 233,145 shares during the period. Hedge funds and other institutional investors own 81.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Truist Financial boosted their price target on shares of Globe Life from $158.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, February 6th. JPMorgan Chase & Co. lifted their price objective on Globe Life from $180.00 to $181.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Evercore set a $157.00 target price on Globe Life in a research report on Wednesday, February 18th. Keefe, Bruyette & Woods restated a “moderate buy” rating and issued a $168.00 target price on shares of Globe Life in a research note on Thursday, March 26th. Finally, Wells Fargo & Company raised their price target on Globe Life from $171.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Globe Life presently has a consensus rating of “Buy” and an average target price of $172.11.

About Globe Life

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.